Results 101 to 110 of about 2,385 (197)

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Российский кардиологический журнал, 2016
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
. .
doaj  

Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y(12) Inhibitor Therapy: The CAMEO Registry [PDF]

BACKGROUND: Little is known about the bleeding risk associated with cangrelor use in patients with myocardial infarction (MI) who are exposed to an oral P2Y(12) inhibitor before coronary angiography.
Kirtane, Ajay J, Washam, Jeffrey B, Basir, Mir B, Bhatt, Deepak L, Diaz, Miguel, Kemp, Steven, Bach, Richard, Jones, W. Schuyler, El-Sabae, Hijrah, Rymer, Jennifer, Ang, Lawrence, Kochar, Ajar, Waksman, Ron, Wang, Tracy Y, Ohman, E. Magnus, Barker, Colin, Sullivan, Alex, Brothers, Leo, Alhanti, Brooke, Garratt, Kirk N, Angiolillo, Dominick J, Wimmer, Neil J, Jenkins, Ronald   +22 more
core  

Cangrelor

JACC: Cardiovascular Interventions, 2016
Mathieu Kerneis, Johanne Silvain, Gilles Montalescot   +2 more
openaire   +1 more source

Revisiting Antiplatelet Therapy in Acute Carotid Tandem Lesions. [PDF]

J Clin Med
Zupan M, Straus L, Kermer P, Papanagiotou P, Frol S.   +4 more
europepmc   +1 more source

Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases. [PDF]

J Neurosurg Case Lessons
Sahin ME, Fulton AT, Deshpande S, Alkhalili K, Hauck EF.   +4 more
europepmc   +1 more source

Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors. [PDF]

Eur Heart J Acute Cardiovasc Care
Gelbenegger G, Lipa AJ, Jorda A, Zilberszac R, Heinz G, Staudinger T, Zauner C, Holzer M, Friedrich G, Plank F, Lang IM, Jilma B, Siller-Matula JM.   +12 more
europepmc   +1 more source

Factors influencing the interpretation of meta-analytic findings in cangrelor research. [PDF]

Crit Care
Bottussi A, D'Andria Ursoleo J, Monaco F, Wieruszewski PM.   +3 more
europepmc   +1 more source

Methodological considerations in meta-analytic evaluation of cangrelor in critically ill patients: a response to Bottussi et al. [PDF]

Crit Care
Hendrianus H, Lee SY, Cho JH, Jo J, Kim SW, Jeong YH.   +5 more
europepmc   +1 more source

Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing. [PDF]

Blood
Barrios DA, Guo S, Powers M, Koseoglu S, Zerbey SS, Lu R, Cermak A, Vayne C, Khan S, Aisiku O, Urman A, Thomas J, Patell RD, Zwicker JI, Flaumenhaft R.   +14 more
europepmc   +1 more source

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Various Bolus and Infusion Doses of Cangrelor [PDF]

Background: Cangrelor (Kengreal(R) is a non-thienopyridine parenteral antiplatelet drug approved as an adjunct for the reduction of periprocedural myocardial infarction and stent thrombosis risk in patients undergoing percutaneous coronary intervention ...
Pham, Le Thien Truc, Adane, Eyob
core   +1 more source